MERCK & CO. INC. (MRK) Stock Price, Forecast & Analysis
USA - NYSE:MRK - US58933Y1055 - Common Stock
MRK Key Statistics, Chart & Performance
The current stock price of MRK is 90.95 USD. In the past month the price increased by 7.38%. In the past year, price decreased by -5.57%.
MRK Latest News, Press Relases and Analysis
MRK Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 44.96 | 935.69B | ||
| JNJ | JOHNSON & JOHNSON | 18.67 | 466.81B | ||
| PFE | PFIZER INC | 7.97 | 145.04B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.43 | 99.17B | ||
| ZTS | ZOETIS INC | 18.95 | 53.23B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.48 | 22.72B | ||
| VTRS | VIATRIS INC | 4.81 | 13.06B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.81 | 11.36B | ||
| CORT | CORCEPT THERAPEUTICS INC | 89.78 | 8.33B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 6.97B | ||
| LGND | LIGAND PHARMACEUTICALS | 28.63 | 4.09B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 3.69B |
Related stock screener links
About MRK
Company Profile
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company is headquartered in Rahway, New Jersey and currently employs 75,000 full-time employees. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The firm sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. The company sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
Company Info
MERCK & CO. INC.
126 East Lincoln Avenue, P.O. Box 2000
Rahway NEW JERSEY 07033 US
CEO: Kenneth C. Frazier
Employees: 75000
Phone: 19087404000
MERCK & CO. INC. / MRK FAQ
What does MRK do?
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company is headquartered in Rahway, New Jersey and currently employs 75,000 full-time employees. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The firm sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. The company sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
What is the stock price of MERCK & CO. INC. today?
The current stock price of MRK is 90.95 USD. The price increased by 4.84% in the last trading session.
What is the dividend status of MERCK & CO. INC.?
MERCK & CO. INC. (MRK) has a dividend yield of 3.78%. The yearly dividend amount is currently 3.1.
What is the ChartMill technical and fundamental rating of MRK stock?
MRK has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
What is the analyst forecast for MRK stock?
33 analysts have analysed MRK and the average price target is 101.03 USD. This implies a price increase of 11.08% is expected in the next year compared to the current price of 90.95.
Should I buy MRK stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on MRK.
What is the Short Interest ratio of MERCK & CO. INC. (MRK) stock?
The outstanding short interest for MERCK & CO. INC. (MRK) is 1.07% of its float.
MRK Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to MRK. When comparing the yearly performance of all stocks, MRK turns out to be only a medium performer in the overall market: it outperformed 45.02% of all stocks.
MRK Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to MRK. MRK has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.
MRK Financial Highlights
Over the last trailing twelve months MRK reported a non-GAAP Earnings per Share(EPS) of 8.81. The EPS increased by 48.07% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 25.79% | ||
| ROA | 13.96% | ||
| ROE | 33.49% | ||
| Debt/Equity | 0.69 |
MRK Forecast & Estimates
33 analysts have analysed MRK and the average price target is 101.03 USD. This implies a price increase of 11.08% is expected in the next year compared to the current price of 90.95.
For the next year, analysts expect an EPS growth of 18.21% and a revenue growth 1.08% for MRK